
Novo Nordisk, NanoVation ink $600M gene therapy deal
2024-09-24
Novo Nordisk has partnered with NanoVation Therapeutics in a $600 million collaboration to develop genetic therapies for cardiometabolic and rare diseases, leveraging NanoVation's long-circulating lipid nanoparticle technology for enhanced RNA delivery. The agreement covers two lead base-editing programs with options for five additional targets, granting Novo exclusive global licensing rights while providing NanoVation with research funding, milestone payments, and future product royalties.
Full story:
AIChE SmartBrief
Chemical engineering news
Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly email newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.
SUBSCRIBE